[HTML][HTML] Tumor-type agnostic, targeted therapies: BRAF inhibitors join the group
In the present review, we briefly discuss the breakthrough advances in precision medicine
using a tumor-agnostic approach and focus on BRAF treatment modalities, the mechanisms …
using a tumor-agnostic approach and focus on BRAF treatment modalities, the mechanisms …
A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::BRAF fusion: a case report and literature review
L Zhang, G Zhang, H Zheng, B Jiang, Y Ju, Q Duan… - Brain Tumor …, 2024 - Springer
Introduction Patients with histiocytic sarcoma occurring in the central nervous system (CNS)
are rare and have a very poor prognosis. The increased use of molecular diagnostic …
are rare and have a very poor prognosis. The increased use of molecular diagnostic …
Oncocytic intraductal carcinoma of parotid gland with a novel AGK::BRAF gene fusion
M Mauramo, J Tarkkanen, A Skalova, I Leivo - Virchows Archiv, 2024 - Springer
Intraductal carcinoma (IDC) is a rare low-grade salivary gland malignancy which occurs
predominantly in the parotid gland [1]. The clinical course is usually indolent, but even …
predominantly in the parotid gland [1]. The clinical course is usually indolent, but even …
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications
Objectives Molecular diagnosis for targeted therapies has been improved significantly in
non-small-cell lung cancer (NSCLC) patients in recent years. Here we report on the …
non-small-cell lung cancer (NSCLC) patients in recent years. Here we report on the …